This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1352458507084595v1 1352458507084595v2 14/4/440    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Marignier, R. Articles by Honnorat, J. Search for Related Content PubMed PubMed Citation Articles by Marignier, R. Articles by Honnorat, J. Pubmed/NCBI databases Substance via MeSH Social Bookmarking                         What's this?

NMO-IgG and Devic's neuromyelitis optica: a French experience

¹ Service de Neurologie A and EDMUS Co-ordinating Center, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 59 boulevard Pinel Lyon Bron cedex, F-69677, France; 2Inserm U 842, Lyon, F-69008, France and 3Université de Lyon, Lyon, F-69003; Université Lyon 1, Lyon, F-69003, France
² Hôpital Civil de Strasbourg, Strasbourg, F-67000, France
³ Service de Neurologie A and EDMUS Co-ordinating Center, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 59 boulevard Pinel Lyon Bron cedex, F-69677, France and 3Université de Lyon, Lyon, F-69003; Université Lyon 1, Lyon, F-69003, France
⁴ CHRU de Lille, Lille, F-59000, France
⁵ 5CHRU de Lille, Lille, F-59000, France
⁶ CHU Fort de France, F-97200, France
⁷ Inserm U 842, Lyon, F-69008, France
⁸ Inserm U 842, Lyon, F-69008, France and 3Université de Lyon, Lyon, F-69003; Université Lyon 1, Lyon, F-69003, France
⁹ Service de Neurologie A and EDMUS Co-ordinating Center, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 59 boulevard Pinel Lyon Bron cedex, F-69677, France nad 3Université de Lyon, Lyon, F-69003; Université Lyon 1, Lyon, F-69003, France

^* To whom correspondence should be addressed.

	Abstract

Background

A serum autoantibody biomarker, NMO-IgG has been recently described in patients with Devic's neuromyelitis optica (DNMO) and so called 'high-risk' patients for this disease. Our objectives were to replicate the test and to assess its usefulness.

Methods

Indirect immunofluorescence with a substrate of adult rat cerebellum and midbrain was used to identify the distinctive NMO-IgG staining pattern. We tested masked sera from 26 patients with DNMO (group 1), 21 patients with idiopathic acute transverse myelitis (ATM) (group 2), 21 patients with bilateral and/or recurrent idiopathic optic neuritis (group 3), 52 patients with classical multiple sclerosis (MS) (group 4), 36 patients with HTLV-1 infection (group 5) and 7 patients with miscellaneous disorders (group 6).

Results

We identified a vascular staining pattern typical of NMO-IgG. This particular staining was observed in 14/26 samples in group 1, 7/21 in group 2 (positive only in longitudinally extensive acute transverse myelitis: 7/13), 4/21 in group 3 (with bilateral loss of vision in all seropositive cases), 5/52 in group 4 (none of them suggestive of DNMO), 0/36 in group 5 and 0/7 in group 6. Sensitivity of the test was 54% considering detection of DNMO (group 1), and specificity was respectively 94% and 90% when considering groups 4, 5 and 6 altogether or group 4 of MS patients only.

Conclusion

Detection of NMO-IgG is contributory to the distinction of DNMO and 'DNMO high-risk' syndromes from MS. This test may allow earlier diagnosis and help therapeutic decisions.

Key Words: Devic's disease; neuromyelitis optica; NMO-IgG; transverse myelitis

First published on January 21, 2008, doi:10.1177/1352458507084595

Multiple Sclerosis 2008;14:440.

A more recent version of this article appeared on May 1, 2008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. M. Magana, S. J. Pittock, V. A. Lennon, B. M. Keegan, B. G. Weinshenker, and C. F. Lucchinetti Neuromyelitis Optica IgG Serostatus in Fulminant Central Nervous System Inflammatory Demyelinating Disease Arch Neurol, August 1, 2009; 66(8): 964 - 966. [Abstract] [Full Text] [PDF]

				J. N. Ratchford, M. E. Quigg, A. Conger, T. Frohman, E. Frohman, L. J. Balcer, P. A. Calabresi, and D. A. Kerr Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies Neurology, July 28, 2009; 73(4): 302 - 308. [Abstract] [Full Text] [PDF]

				J. Cabrera-Gomez, M Bonnan, A Gonzalez-Quevedo, A Saiz-Hinarejos, R Marignier, S Olindo, F Graus, D Smadja, H Merle, L Thomas, et al. Neuromyelitis optica positive antibodies confer a worse course in relapsing-neuromyelitis optica in Cuba and French West Indies Multiple Sclerosis, July 1, 2009; 15(7): 828 - 833. [Abstract] [PDF]

				D. Bichuetti, E. Oliveira, N. Souza, R. Rivero, and A. Gabbai Neuromyelitis optica in Brazil: a study on clinical and prognostic factors Multiple Sclerosis, May 1, 2009; 15(5): 613 - 619. [Abstract] [PDF]

				H Zephir, I Fajardy, O Outteryck, F Blanc, N Roger, M Fleury, G Rudolf, R Marignier, S Vukusic, C Confavreux, et al. Is neuromyelitis optica associated with human leukocyte antigen? Multiple Sclerosis, May 1, 2009; 15(5): 571 - 579. [Abstract] [PDF]

				M Bonnan, R Valentino, S Olindo, H Mehdaoui, D Smadja, and P Cabre Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder Multiple Sclerosis, April 1, 2009; 15(4): 487 - 492. [Abstract] [PDF]